FLT3 and acute myeloid leukemia: New therapeutic approaches based on inhibitors of key oncoproteins in AML, such as FLT3, IDH1/2 and BCL2, are being gradually introduced by healthcare systems worldwide [3], but responses are heterogeneous, and new therapeutic approaches are needed to treat refractory and relapsed patients.